{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:20:05Z","timestamp":1740165605651,"version":"3.37.3"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010578","name":"Deutsche Gesellschaft f\u00fcr Kardiologie-Herz und Kreislaufforschung.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","interventional.theclinics.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.iccl.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:05:55Z","timestamp":1723125955000},"page":"451-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulation of Platelet Activation and Coagulation"],"prefix":"10.1016","volume":"13","author":[{"given":"Tobias","family":"Harm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin Anne","family":"Lydia Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.iccl.2024.06.001_bib1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"31","key":"10.1016\/j.iccl.2024.06.001_bib2","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.001_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamacardio.2020.6814","article-title":"Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model","volume":"6","author":"Urban","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10073","key":"10.1016\/j.iccl.2024.06.001_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.001_bib5","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10270","key":"10.1016\/j.iccl.2024.06.001_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(20)32519-8","article-title":"Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets","volume":"397","author":"D'Ascenzo","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.iccl.2024.06.001_bib7","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.001_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"48","key":"10.1016\/j.iccl.2024.06.001_bib9","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1093\/eurheartj\/ehac402","article-title":"Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54","volume":"43","author":"Bonaca","year":"2022","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.iccl.2024.06.001_bib10","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"10293","key":"10.1016\/j.iccl.2024.06.001_bib11","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.001_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.338","article-title":"The reversible P2Y(12) antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat","volume":"5","author":"Rey","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"33","key":"10.1016\/j.iccl.2024.06.001_bib13","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/eurheartj\/ehz807","article-title":"Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes","volume":"41","author":"Storey","year":"2020","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.001_bib14","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jacc.2020.03.059","article-title":"Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction","volume":"75","author":"Sinnaeve","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2024.06.001_bib15","unstructured":"US National Library of Medicine. ClinicalTrials.gov, Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04957719, Study Start 2021-08-14, Study Completion (Estimated) 2025-08-13, (Accessed July 30 2024)."},{"issue":"15","key":"10.1016\/j.iccl.2024.06.001_bib16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the Secondary Prevention of Atherothrombotic Events","volume":"366","author":"Morrow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.001_bib17","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.4244\/EIJ-D-21-00287","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb\/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction","volume":"17","author":"Bor","year":"2021","journal-title":"EuroIntervention"},{"issue":"17","key":"10.1016\/j.iccl.2024.06.001_bib18","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.001_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066960","article-title":"The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke","volume":"8","author":"Goebel","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.001_bib20","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1161\/STROKEAHA.121.037006","article-title":"Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial","volume":"53","author":"Uphaus","year":"2022","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.001_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/jamacardio.2021.0475","volume":"6","author":"Mayer","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.001_bib22","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1161\/STROKEAHA.122.039790","article-title":"Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke","volume":"53","author":"Wichaiyo","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.iccl.2024.06.001_bib23","unstructured":"US National Library of Medicine. ClinicalTrials.gov, Available at: https:\/\/ClinicalTrials.gov\/show\/NCT05070260, Study Start 2021-09-23, Study Completion (Actual) 2024-04-30, (Accessed July 30 2024)."},{"issue":"10","key":"10.1016\/j.iccl.2024.06.001_bib24","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","article-title":"Human target validation of phosphoinositide 3-kinase (PI3K)\u03b2: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K\u03b2 inhibitor","volume":"10","author":"Nylander","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.001_bib25","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.13027","article-title":"Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase \u03b2 inhibition and aspirin in man","volume":"13","author":"Nylander","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.iccl.2024.06.001_bib26","unstructured":"US National Library of Medicine. ClinicalTrials.gov, Available at: https:\/\/ClinicalTrials.gov\/show\/NCT05363397, Study Start 2023-09-27, Study Completion (Estimated) 2025-05-01, (Accessed July 30 2024)."},{"issue":"8","key":"10.1016\/j.iccl.2024.06.001_bib27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.cellsig.2007.03.012","article-title":"Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice","volume":"19","author":"Sun","year":"2007","journal-title":"Cell Signal"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.001_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in\u00a0Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.001_bib29","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/cvr\/cvab238","article-title":"Acute coronary syndrome is associated with a substantial change in the platelet lipidome","volume":"118","author":"Harm","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.iccl.2024.06.001_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-023-02260-x","article-title":"Large-scale lipidomics profiling reveals characteristic lipid signatures associated with an increased cardiovascular risk","author":"Harm","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.iccl.2024.06.001_bib31","article-title":"Statin Treatment Is Associated with Alterations in the Platelet Lipidome","author":"Harm","year":"2023","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.001_bib32","doi-asserted-by":"crossref","first-page":"e806","DOI":"10.1038\/cddis.2013.317","article-title":"Targeting annexin A7 by a small molecule suppressed the activity of phosphatidylcholine-specific phospholipase C in vascular endothelial cells and inhibited atherosclerosis in apolipoprotein E\u2212\/\u2212 mice","volume":"4","author":"Li","year":"2013","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.001_bib33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.001_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.001_bib35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"Konstantinides","year":"2019","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.iccl.2024.06.001_bib36","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.001_bib37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"issue":"26","key":"10.1016\/j.iccl.2024.06.001_bib38","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2303048","article-title":"Early versus Later Anticoagulation for Stroke with Atrial Fibrillation","volume":"388","author":"Fischer","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.001_bib39","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300235","article-title":"Apixaban versus Aspirin for Embolic Stroke of Undetermined Source","volume":"3","author":"Geisler","year":"2024","journal-title":"NEJM Evidence"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.001_bib40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.001_bib41","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.001_bib42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","article-title":"Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial","volume":"141","author":"Lopes","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.001_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ehjcvp\/pvab043","article-title":"Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials","volume":"8","author":"Galli","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.001_bib44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.001_bib45","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in Peripheral Artery Disease after Revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.iccl.2024.06.001_bib46","article-title":"Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.001_bib47","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1055\/s-0041-1735971","article-title":"The Association between Factor XI Deficiency and the Risk of Bleeding, Cardiovascular, and Venous Thromboembolic Events","volume":"122","author":"Sharman Moser","year":"2022","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.001_bib48","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.001_bib49","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.001_bib50","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/ATVBAHA.123.318781","article-title":"New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors","volume":"43","author":"Chan","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.001_bib51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for Prevention of Venous Thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.001_bib52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.001_bib53","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.iccl.2024.06.001_bib54","unstructured":"US National Library of Medicine. ClinicalTrials.gov, Available at: https:\/\/ClinicalTrials.gov\/show\/NCT05171049, Study Start 2022-05-05, Study Completion (Estimated) 2025-09, (Accessed July 30 2024)."},{"key":"10.1016\/j.iccl.2024.06.001_bib55","unstructured":"US National Library of Medicine. ClinicalTrials.gov, Available at: https:\/\/ClinicalTrials.gov\/show\/NCT05171075, Study Start 2022-09-27, Study Completion (Estimated) 2025-09, (Accessed July 30 2024)."},{"key":"10.1016\/j.iccl.2024.06.001_bib56","unstructured":"US National Library of Medicine. ClinicalTrials.gov Available at: https:\/\/ClinicalTrials.gov\/show\/NCT05712200, Study Start 2022-12-27, Study Completion (Estimated) 2025-03, (Accessed July 30 2024)."},{"issue":"23","key":"10.1016\/j.iccl.2024.06.001_bib57","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the Prevention of Venous Thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10357","key":"10.1016\/j.iccl.2024.06.001_bib58","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.001_bib59","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A\u00a0Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"issue":"10333","key":"10.1016\/j.iccl.2024.06.001_bib60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.001_bib61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.iccl.2024.06.001_bib62","unstructured":"US National Library of Medicine. ClinicalTrials.gov Available at: https:\/\/ClinicalTrials.gov\/show\/NCT05702034, Study Start 2023-02-15, Study Completion (Estimated) 2026-12-09, (Accessed July 30 2024)."},{"issue":"3","key":"10.1016\/j.iccl.2024.06.001_bib63","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T22:55:14Z","timestamp":1725836114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745824000609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2211745824000609"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.001","relation":{},"ISSN":["2211-7458"],"issn-type":[{"type":"print","value":"2211-7458"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulation of Platelet Activation and Coagulation","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}